| Scorecard |
|---|
|
---
|
|
Lipper
---
|
|
Zacks Investment Research
---
|
|
Standard & Poor's
---
|
|
TheStreet.com
---
|
U.S. News evaluated 38 Health Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.
Performance
The fund has returned 30.22 percent over the past year.
| Trailing Returns | Updated 04.30.2013 |
|---|---|
| Year to date | 18.7% |
| 1 Year | 30.2% |
| 3 Years (Annualized) | N/A |
| 5 Years (Annualized) | N/A |
| 10 Years (Annualized) | N/A |
Summary
The investment seeks long-term capital appreciation. The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in common stocks of companies engaged, at the time of investment, in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences. While it may invest in companies of any size, the majority of its assets are expected to be invested in large- and mid-capitalization companies. The fund may invest up to 35% of its total assets in foreign securities (including emerging market securities).
Fees
Fees are Low compared to funds in the same category.
John Hancock II Health Sciences Fund has an expense ratio of 1.06 percent.
Risk
Risk is N/A compared to funds in the same category according to Morningstar.
